For example, lung adenocarcinomas harboring mutations in LKB1 are highly aggressive, treatment-refractory, and insensitive to immune checkpoint inhibitors9,24–26, representing a major clinical challenge. The gene discussed is STK11; the disease is lung adenocarcinoma.